Arecor And Trx Biosciences Establish Research Collaboration
The company that developed the technology behind Sanofi’s purchase of Inhibrx said that royalty obligations won’t change with the acquisition.
Arecor Therapeutics plc(œArecor or the œGroup) FIRST PRODUCT INCORPORATING ARECOR™S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE First commercial sale triggers milestone payment and future...
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...
Cambridge, UK, 11 October 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces headline results from the second Phase I clinical trial of its ultra-rapid acting insulin, AT247, which support its potential to facilitate a fully closed loop artificial pancreas.
Arecor Therapeutics has announced that the European Patent Office has granted two patents –EP3592383B1 and EP3592385B1 – protecting the group’s novel formulations of high-concentration adalimumab until 2038.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology and neurology, today announced that Tetris Pharma—its commercialization partner for Ogluo in the UK, EEA, and Switzerland—will be acquired by Arecor Therapeutics (AIM: AREC), a UK-based, publicly traded, globally focused biopharmaceutical company, contingent upon a successful capital offering by Arecor Therapeutics. Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA.
Arecor Therapeutics PLC (AIM:AREC) has unveiled acquisition plans designed to accelerate its commercial aspirations.
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals anticipated in H2 and beyondKey data for...
Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat, to develop improved, stable, high concentration liquid formulations of its proprietary products. The company will fund the initial development work and has the option to acquire the rights to the new proprietary formulations and associated intellectual property under a technology licensing model.